Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 15;8(3):513-8.
doi: 10.1021/cb3006193. Epub 2012 Dec 27.

Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease

Affiliations

Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease

Jennifer E Foulkes-Murzycki et al. ACS Chem Biol. .

Abstract

Understanding the interdependence of multiple mutations in conferring drug resistance is crucial to the development of novel and robust inhibitors. As HIV-1 protease continues to adapt and evade inhibitors while still maintaining the ability to specifically recognize and efficiently cleave its substrates, the problem of drug resistance has become more complicated. Under the selective pressure of therapy, correlated mutations accumulate throughout the enzyme to compromise inhibitor binding, but characterizing their energetic interdependency is not straightforward. A particular drug resistant variant (L10I/G48V/I54V/V82A) displays extreme entropy-enthalpy compensation relative to wild-type enzyme but a similar variant (L10I/G48V/I54A/V82A) does not. Individual mutations of sites in the flaps (residues 48 and 54) of the enzyme reveal that the thermodynamic effects are not additive. Rather, the thermodynamic profile of the variants is interdependent on the cooperative effects exerted by a particular combination of mutations simultaneously present.

PubMed Disclaimer

Figures

Figure 1
Figure 1
HIV-1 protease colored by sequence conservation (41). Residues colored red are invariant in both untreated and treated populations of patients. Residues colored yellow are invariant only in the untreated population. Invariant glycine residues are colored blue. (a) The protease structure in unliganded (PDB code: 1HHP) and (b) liganded (PDB code: 1HXB) state. The side chains of the catalytic aspartic acids Asp25 in both monomers, as well as mutation sites Leu10, Ile54, and Val82 are displayed.
Figure 2
Figure 2
Changes in the thermodynamic parameters of binding relative to wild-type (WT) protease. The dark blue, magenta and cyan bars are changes in the free energy (ΔΔG), enthalpy (ΔΔH), and entropy (Δ(-TΔS)) of binding, respectively.
Figure 3
Figure 3
Positions of mutated residues displayed on inhibitor-bound HIV-1 protease structure (WT protease bound to SQV, PDB code 1HXB). Ile10, Gly48, Ile54, and Val82 side chains are in cyan van der Waal spheres. The SQV molecule is in stick representation and colored according to atom type, with grey for carbon, blue for nitrogen, and red for oxygen. (a) Front view, showing that neither residue 10 nor residue 54 is in contact with the inhibitor. (b) Top view, showing that residue 54 is in close contact with Ile50 of the other monomer.

References

    1. Hogg RS, Heath KV, Yip B, Craib KJP, O’Shaughnessy MV, Schechter MT, Montaner JSG. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–454. - PubMed
    1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD, The HIVOSI Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860. - PubMed
    1. The HIV-Causal Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;24:123–137. - PMC - PubMed
    1. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol. 2004;78:12012–12021. - PMC - PubMed
    1. Todd MJ, Luque I, Velazquez-Campoy A, Freire E. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry. 2000;39:11876–11883. - PubMed

Publication types